A Phase 3 interventional study of Immune globulin subcutaneous (Human) in Primary Immune Deficiency Disorder, sponsored by CSL Behring. Completed at 9 sites in Japan. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2013-04-09.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 18 in phase 3, and was the 14th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: Up to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
14 studies in Primary Immunodeficiency Diseases by CSL Limited: none open now, none under way, none of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 10th registered.
CSL Limited’s Primary Immunodeficiency Diseases studies by the year they started, since 2006.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
Among CSL Limited’s 14 in Primary Immunodeficiency Diseases:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Immune globulin subcutaneous (Human)
IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
Also known as: Hizentra
Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion
The rate was calculated by counting all newly developed or worsened AEs within a subject and dividing by the total number of IgPro20 infusions administered to this subject. Subsequently, the median of these individual AE rates per infusion was calculated. AE rates were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).
Time frame: 24 weeks
Overall Rate of AEs Per Infusion
The rate was calculated by counting all newly developed or worsened AEs during the treatment period in all subjects and dividing the total number of AEs by the total number of IgPro20 infusions administered. In addition, individual AEs were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]). The AE rates per infusion by severity and causal relationship to study medication were calculated by dividing the number of AEs in each category by the total number of IgPro20 infusions.
Time frame: 24 weeks
Number of Subjects With Newly Developing or Worsening AEs
Number of subjects with AEs, overall and classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).
Time frame: 24 weeks
Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good'
Subjects assessed their overall perception of local tolerability at the infusion site throughout the study in the subject diary within a time window of 24 h to 72 h after the end of the latest infusion by assessing it as "very good", "good", "fair", or "poor". The reported percentage represents the percentage of subjects with local tolerability assessments of "very good" or "good" at any given study infusion.
Time frame: 24 to 72 hours after infusion
IgG Trough Level
Serum IgG trough levels at the completion visit compared to the baseline visit of the follow-up study. IgG trough levels at baseline, at the completion visit, and the change from baseline to the completion visit are shown
Time frame: 24 weeks
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)
SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess. The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the FAS and PPS and adjusted to 365 days.
Time frame: 24 weeks
Number of Infection Episodes (Serious and Non-serious)
Time frame: 24 weeks
Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections.
Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections.
Time frame: 24 weeks
Number of Days of Hospitalization Due to Infections.
Median number of days of hospitalization due to infections.
Time frame: 24 weeks
Duration of Use of Antibiotics for Infection Prophylaxis and Treatment
Median number of days of use of antibiotics for infection prophylaxis and/or treatment
Time frame: 24 weeks
Rate of Infection Episodes (Serious and Non-serious)
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the FAS population and the PPS population and adjusted to 365 days.
Time frame: 24 weeks
This multicenter study enrolled subjects at nine study centers in Japan who had participated in the preceding pivotal study ZLB06_002CR (CT.gov identifier: NCT01199705).
| Milestone | IgPro20 |
|---|---|
| Started | 23 |
| Completed | 22 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
The rate was calculated by counting all newly developed or worsened AEs within a subject and dividing by the total number of IgPro20 infusions administered to this subject. Subsequently, the median of these individual AE rates per infusion was calculated. AE rates were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).
| AEs per infusion | IgPro20 |
|---|---|
| All AEs | 0.167 (0 to 1.71) |
| Mild AEs | 0.125 (0 to 1.71) |
| Moderate AEs | 0 (0 to 0.04) |
| Severe AEs | 0 (0 to 1.00) |
| Not related or unlikely related AEs | 0.125 (0 to 0.75) |
| At least possibly related AEs | 0 (0 to 1.00) |
The rate was calculated by counting all newly developed or worsened AEs during the treatment period in all subjects and dividing the total number of AEs by the total number of IgPro20 infusions administered. In addition, individual AEs were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]). The AE rates per infusion by severity and causal relationship to study medication were calculated by dividing the number of AEs in each category by the total number of IgPro20 infusions.
| AEs per infusion | IgPro20 |
|---|---|
| All AEs | 0.346 |
| Mild AEs | 0.342 |
| Moderate AEs | 0.002 |
| Severe AEs | 0.002 |
| Not related or unlikely related AEs | 0.210 |
| At least possibly related AEs | 0.136 |
Number of subjects with AEs, overall and classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).
| participants | IgPro20 |
|---|---|
| All AEs | 22 |
| Mild AEs | 21 |
| Moderate AEs | 1 |
| Severe AEs | 1 |
| Not related or unlikely related | 12 |
| At least possibly related | 10 |
Subjects assessed their overall perception of local tolerability at the infusion site throughout the study in the subject diary within a time window of 24 h to 72 h after the end of the latest infusion by assessing it as "very good", "good", "fair", or "poor". The reported percentage represents the percentage of subjects with local tolerability assessments of "very good" or "good" at any given study infusion.
| percentage of infusions | IgPro20 |
|---|---|
| Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good' | 85.4 |
Serum IgG trough levels at the completion visit compared to the baseline visit of the follow-up study. IgG trough levels at baseline, at the completion visit, and the change from baseline to the completion visit are shown
| g/L | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Baseline | 7.469 ± 1.3943 | 7.586 ± 1.3363 |
| Completion visit | 8.914 ± 4.0502 | 8.227 ± 1.5458 |
| Change from baseline to the completion vist | 1.445 ± 3.4379 | 0.642 ± 0.7687 |
SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess. The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the FAS and PPS and adjusted to 365 days.
| SBIs per subject year | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) | 0.00 | 0.00 |
| infection episodes | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Number of Infection Episodes (Serious and Non-serious) | 43 | 38 |
Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections.
| days | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections. | 0 (0 to 12) | 0 (0 to 9) |
Median number of days of hospitalization due to infections.
| days | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Number of Days of Hospitalization Due to Infections. | 0 (0 to 11) | 0 (0 to 0) |
Median number of days of use of antibiotics for infection prophylaxis and/or treatment
| days | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Duration of Use of Antibiotics for Infection Prophylaxis and Treatment | 91.5 (6 to 170) | 154.0 (6 to 170) |
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the FAS population and the PPS population and adjusted to 365 days.
| infection episodes per subject year | IgPro20 - FAS | IgPro20 - PPS |
|---|---|---|
| Rate of Infection Episodes (Serious and Non-serious) | 4.20 | 4.32 |
Collected over For the duration of the study, that is, 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 | — | 1/23 (4.3%) | 20/23 (87%) |
| Event | IgPro20 |
|---|---|
| EncephalitisNervous system disorders | 1/23 |
| Event | IgPro20 |
|---|---|
| NasopharyngitisInfections and infestations | 6/23 |
| EczemaSkin and subcutaneous tissue disorders | 6/23 |
| Injection site painGeneral disorders | 5/23 |
| Upper respiratory tract infectionInfections and infestations | 5/23 |
| Dental cariesGastrointestinal disorders | 4/23 |
| Arthropod biteInjury, poisoning and procedural complications | 3/23 |
| HeadacheNervous system disorders | 3/23 |
| Injection site indurationGeneral disorders | 2/23 |
| PyrexiaGeneral disorders | 2/23 |
| BronchitisInfections and infestations | 2/23 |
| Age Continuous(years) | IgPro20 |
|---|---|
| Mean | 20.8 ± 13.68 |
| Sex: Female, Male(Participants) | IgPro20 |
|---|---|
| Female | 9 |
| Male | 14 |
The record gives a start of Apr 2011, a primary completion of Feb 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Primary Immunodeficiency Diseases →